Somewhat Negative News Coverage Somewhat Unlikely to Affect argenx (ARGX) Share Price

Media coverage about argenx (NASDAQ:ARGX) has been trending somewhat negative this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. argenx earned a coverage optimism score of -0.01 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.5176796456059 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news articles that may have impacted Accern’s analysis:

Shares of ARGX traded up $0.17 during mid-day trading on Friday, reaching $93.83. The company’s stock had a trading volume of 64,500 shares, compared to its average volume of 137,129. The firm has a market capitalization of $2.95 billion, a P/E ratio of -66.66 and a beta of 2.42. argenx has a 1 year low of $20.50 and a 1 year high of $103.00.

A number of brokerages have issued reports on ARGX. Cowen reaffirmed a “buy” rating on shares of argenx in a research note on Wednesday, June 6th. Wedbush reaffirmed an “outperform” rating and set a $92.00 price target (down from $93.00) on shares of argenx in a research note on Thursday, May 10th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $130.00 price target on shares of argenx in a research note on Thursday, June 7th. JMP Securities raised their price objective on argenx from $93.00 to $130.00 and gave the stock a “positive” rating in a research note on Monday, June 18th. Finally, ValuEngine raised argenx from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. argenx currently has a consensus rating of “Buy” and a consensus price target of $122.83.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Further Reading: What does earnings per share mean?

Insider Buying and Selling by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with's FREE daily email newsletter.

Leave a Reply